Professor Aarsland will assist Cognetivity by providing scientific expertise and access to extensive network of clinical and industry connections
VANCOUVER, BC, March 30, 2021 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB) today announced the appointment of Professor Dag Aarsland to its advisory board with immediate effect.
An internationally-renowned figure in the world of medicine, Dag currently sits as Chair of Old Age Psychiatry at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Through the course of his distinguished career, he has also held professorships at the Universities of Bergen and Oslo, as well as the prestigious Karolinska Institute in Stockholm.
Dag completed his PhD thesis on language disorders in patients with Alzheimer’s disease in 1998, and has since published more than 600 papers across the spectrum of dementia research, specialising particularly in dementia with Lewy bodies and Parkinson’s disease. He remains involved in a variety of ground-breaking research efforts, including PROTECT – an online cohort study tracking annual changes in cognitive function in 50,000 people over a 25-year period.
Dag has a vast network of long-time collaborators that extends well beyond the world of academia. Within the pharmaceutical industry, he has acted as a consultant to global firms such as AstraZeneca, Novartis, Lundbeck and Biogen. He also remains active in the clinical sphere, continuing his work as a geriatric psychiatrist at South London and Maudsley NHS Foundation Trust, the largest mental health trust in the UK.
“We’re thrilled to have Dag join us,” said Dr Sina Habibi, Cognetivity’s CEO. “He is without question one of the leading lights in the field of old age psychiatry, not only in the UK but across the world. We look forward to drawing on his immense clinical and scientific knowledge, and also having our technology introduced to his vast network which spans leadership in both the healthcare and pharmaceutical industries.”
“Dag has actually been part of the Cognetivity story for some time, acting as Chief Investigator in the validation study of our Integrated Cognitive Assessment across thirteen NHS trusts. The fact that he has seen in great detail how our platform works and is now keen to further his involvement is exceptional validation of our technology and our commercial approach.”
Commenting on the announcement, Professor Aarsland said: “I’m very excited to be involved more closely with Cognetivity’s work. As someone who cares deeply about improving patient outcomes by challenging the status quo in clinical practice, I find their unique approach to measuring cognitive function inspiring.”
“I believe this work could make a big, positive difference to patient care, particularly at the primary care stage, where it addresses a huge unmet need in healthcare.” he added. “I look forward to working with the Cognetivity team, using my experience and network to help accelerate their progress, to help as many people as possible.”
About Cognetivity Neurosciences Ltd.
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain to support diagnosis of dementia. It has achieved regulatory approval for clinical use in the UK and Europe with future clinical approval anticipated in North America and elsewhere in the world.
Innovate UK EDGE: www.innovateukedge.ukri.org
ON BEHALF OF THE BOARD
Chief Executive Officer and Director
The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.
The Exchange does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Cognetivity Neurosciences Ltd
For further information: For media enquiries, please contact: Josh Stanbury, email@example.com, 416-628-7441